Soligenix Inc. (NASDAQ: SNGX) Advances Rare Disease Treatment with FDA Orphan Designation
The FDA’s orphan drug designation for dusquetide follows encouraging phase 2a clinical trial results demonstrating both biological efficacy and a favorable safety profile. CEO notes that “the FDA's decision to grant orphan drug designation to the SGX945 program signifies an important step for Soligenix.” Phase 2a pilot data demonstrated clinically meaningful improvements in oral aphthous ulcer healing. Soligenix (NASDAQ: SNGX) has taken a decisive step forward in the fight against rare diseases, announcing that the FDA has granted orphan drug designation to its investigational therapy dusquetide for the treatment of Behçet’s disease (https://ibn.fm/0t1aK). This key FDA designation underscores not only…